BRAWLEY OTIS W 4

What Happened Otis W. Brawley, a director of Lyell Immunopharma (LYEL), received a grant of derivative securities covering 9,250 shares on June 10, 2026. The transaction is reported as an acquisition (grant) with a reported price of $0.00 (derivative). This is an award of option-style shares that will convert to or vest as described below — not an open-market purchase or sale.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely filing).
• Grant: 9,250 derivative shares reported at $0.00 (transaction code A = award/grant).
• Vesting: Per the filing, the option shares vest on the earlier of (a) the date of the next annual meeting after June 10, 2026 (or immediately prior if service ends), or (b) the first anniversary of June 10, 2026, subject to continuous service.
• Reverse split: All amounts reflect a 1-for-20 reverse stock split effective May 30, 2025 (footnote).
• Shares owned after the transaction: not specified in the provided filing details.

Context This is a compensation-related derivative award to a director (common for board service) rather than a market purchase or sale. For retail investors: such grants are routine director compensation and do not by themselves indicate buy/sell intent. The award vests based on continued service and timing of the next annual meeting, so the economic impact depends on future vesting and any exercise terms.